In addition, the efficacies against MM of a number of epigenetic drugs, including a DNA methyltransferase (DNMT) inhibitor (Azacitidine), a BET inhibitor (CPI-0610), and HDAC inhibitors (Vorinostat, Belinostat and CI-994), as well as a combination of DNMT and HDAC inhibitors (Azacitidine plus phenylbutyrate) have been tested in clinical trials3,5. This evidence concerns the gene HDAC9 and Miyoshi myopathy.